UNITED STATES

                       SECURITIES AND EXCHANGE COMMISSION

                             Washington D. C. 20549

                                     ------

                                   FORM 10-QSB

                Quarterly Report Pursuant to Section 13 or 15(d)
                     of the Securities Exchange Act of 1934

For the quarter ended March 31, 2003            Commission File Number 000-28876

                           INTEGRATED BIOPHARMA, INC.
                  (f/k/a Integrated Health Technologies, Inc.)
             (Exact name of registrant as specified in its charter)

                   Delaware                                  22-2407475
       (State or other jurisdiction of                     (I.R.S. Employer
        incorporation or organization)                    Identification No.)

               225 Long Avenue
            Hillside, New Jersey                                 07205
   (Address of principal executive offices)                    (Zip code)

Registrant's telephone number, including area code: (973) 926-0816

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.

                                 Yes|X|    No |_|

Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date.

        Class                              Outstanding as of April 30, 2003
-----------------------                    --------------------------------
Common Stock, Par Value                                10,156,439


<PAGE>


The Company is restating its previously issued financial statements for the
quarter ended March 31, 2003 to correct an error in the accounting treatment
related to previously disclosed acquisition costs. The amounts presented herein
reflect the restatement of these financial statements.

It was determined that the acquisition of 50% of Natex LLC, described in Note
12D was with a controlled related party and that the investment should be
recorded at carryover basis (zero). The common shares issued (market value
$1,598,276) in connection with this acquisition were recorded at market value.
Such amount then reduced paid-in capital in accordance with accounting for
transactions with common control entities.

The effects of this restatement are presented in Item 2 "Management's Discussion
and Analysis of Financial Condition and Results of Operations" and Note 12D to
Notes to the Consolidated Financial Statements of this Form 10-QSB. The effects
of this restatement impact the Consolidated Balance Sheet and Consolidated
Statement of Stockholders' Equity.

<PAGE>


INTEGRATED BIOPHARMA, INC.

INDEX
--------------------------------------------------------------------------------

<TABLE>
<S>                                                                     <C>
Part I:   Financial Information

Item 1: Consolidated Financial Statements

        Consolidated Balance Sheet as of March 31, 2003
        [Restated/Unaudited]...........................................  1 - 2

        Consolidated Statement of Stockholders' Equity [Unaudited]
        for the nine months ended March 31, 2003 [Restated]............  3

        Consolidated Statements of Operations [Unaudited]
        for the three months ended  March 31, 2003, [Restated]
        and 2002 and for the nine months ended March 31, 2003
        [Restated] and 2002............................................  4

        Consolidated Statements of Cash Flows [Unaudited]
        for nine months ended March 31, 2003, [Restated] and 2002......  5 - 6

        Notes to Consolidated Financial Statements [Unaudited].........  7 - 14

Item 2: Management's Discussion and Analysis of Financial Condition
        And Results of Operations......................................  15 - 19

Item 3: Controls and Procedures........................................  20

Part II: Other Information.............................................  21

Signature..............................................................  22
</TABLE>
                                   ---------

<PAGE>


INTEGRATED BIOPHARMA, INC.

CONSOLIDATED BALANCE SHEET AS OF MARCH 31, 2003
[UNAUDITED] [RESTATED]
--------------------------------------------------------------------------------

Assets:                                                              (Restated)
Current Assets:
        Cash and Cash Equivalents                                   $  1,637,213
        Accounts Receivable - Net                                      1,480,133
        Deferred Income Taxes                                             52,000
        Inventories                                                    4,279,216
        Prepaid Federal and State Income Taxes                            81,231
        Prepaid Expenses and Other Current Assets                        753,245
                                                                    ------------

        Total Current Assets                                           8,283,038
                                                                    ------------

Property and Equipment - Net                                           2,325,167
                                                                    ------------

Other Assets:
        Deferred Tax Asset                                                82,000
        Patents and Unpatented Technological Expertise                   497,000
        Security Deposits and Other Assets                                92,149
                                                                    ------------

        Total Other Assets                                               671,149
                                                                    ------------

Total Assets                                                        $ 11,279,354
                                                                    ============

See accompanying notes to condensed consolidated financial statements.

                                       1


<PAGE>


INTEGRATED BIOPHARMA, INC.

CONSOLIDATED BALANCE SHEET AS OF MARCH 31, 2003
[UNAUDITED] [RESTATED]
--------------------------------------------------------------------------------

Liabilities and Stockholders' Equity:                                (Restated)
Current Liabilities:
        Accounts Payable                                            $  2,181,964
        Accrued Expenses and Other Current Liabilities                   151,290
        Customer Advances                                                425,881
        Capital Lease Obligation                                           8,597
                                                                    ------------

        Total Current Liabilities                                      2,767,732
                                                                    ------------

Non-Current Liabilities:
        Capital Lease Obligation                                           5,593
                                                                    ------------

        Total Non-Current Liabilities                                      5,593
                                                                    ------------

        Commitments and Contingencies [9]                                     --
                                                                    ------------

Stockholders' Equity:
        Preferred Stock - Authorized 1,000,000 Shares,
        $.002 Par Value, No Shares Issued                                     --

        Common Stock - Authorized 25,000,000 Shares,
        $.002 Par Value, 10,156,439 Shares Issued and
        Outstanding                                                       20,313

        Additional Paid-in Capital                                     6,295,894

        Retained Earnings                                              2,218,653
                                                                    ------------

                                                                       8,534,860
        Less, Treasury Stock at cost, 25,800 shares                     (28,831)
                                                                    ------------
        Total Stockholders' Equity                                     8,506,029
                                                                    ------------

        Total Liabilities and Stockholders' Equity                  $ 11,279,354
                                                                    ============

See accompanying notes to condensed consolidated financial statements.

                                       2


<PAGE>


INTEGRATED BIOPHARMA, INC.

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
FOR THE NINE MONTHS ENDED MARCH 31, 2003
[UNAUDITED] [RESTATED]
--------------------------------------------------------------------------------

<TABLE>
<CAPTION>
                                                       Additional                                            Total
                      Common Stock         Preferred     Paid-In     Retained       Treasury Stock        Stockholders'
                   Shares      Par Value     Stock      Capital      Earnings      Shares      Cost         Equity
                   ------      ---------     -----      -------      --------      ------      ----         ------
<S>                <C>         <C>         <C>         <C>           <C>           <C>       <C>          <C>
Balance-
July 1, 2002       6,228,720   $12,457     $    --     $ 6,113,582   $ 1,487,567   25,800    $ (28,831)   $ 7,584,775

Exercise of
Stock Options
For cash           1,100,000     2,200          --          99,050            --       --            --       101,250

Acquisition of
NuCycle
Therapy, Inc.
(related
party)  for
Common Shares        368,833       738          --       (115,820)            --       --            --     (115,082)

Acquisition of
50% of Natex,
LLC for Common
Shares             2,458,886     4,918          --       1,593,358            --       --            --     1,598,276

Reduction of
paid-in capital
due to common
control accounting
related to common
stock issued in
acquisition of
50% of Natex,
LLC                                                    (1,598,276)                                        (1,598,276)

Income Tax
Benefit From
Exercise of
Stock Options             --        --          --         204,000            --       --            --       204,000

Net Income for
the nine
months ended
March 31, 2003            --        --          --              --       731,086       --            --       731,086
                  ----------   -------     -------     -----------   -----------   ------    ----------   -----------

Balance-
March 31, 2003
(Restated)
                  10,156,439   $20,313     $    --     $ 6,295,894   $ 2,218,653   25,800    $ (28,831)   $ 8,506,029
                  ==========   =======     =======     ===========   ===========   ======    ==========   ===========
</TABLE>

 See accompanying notes to condensed consolidated financial statements.

                                       3


<PAGE>


INTEGRATED BIOPHARMA, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS
[UNAUDITED]
--------------------------------------------------------------------------------

<TABLE>
<CAPTION>
                                       Three months ended               Nine months ended
                                            March 31,                        March 31,
                                       ------------------               -----------------

                                        2003          2002             2003             2002
                                        ----          ----             ----             ----

<S>                                 <C>            <C>             <C>             <C>
Sales                               $ 6,670,254    $ 5,278,366     $ 17,464,163    $ 16,739,241

Cost of Sales                         5,266,734      4,072,267       13,564,430      13,245,102
                                    -----------    -----------     ------------    ------------

Gross Profit                          1,403,520      1,206,099        3,899,733       3,494,139

Selling and Administrative Expenses   1,111,528        984,936        2,868,664       2,966,444
                                    -----------    -----------     ------------    ------------

Operating Income                        291,992        221,163        1,031,069         527,695
                                    -----------    -----------     ------------    ------------

Other Income [Expense]:
Other Income                            103,982         82,994          268,148         269,050
Gain on Settlement of Lawsuit                --             --               --       1,157,960
Interest Expense                          (840)        (1,860)          (4,469)        (41,584)
Interest and Investment Income            4,491          3,666           21,799          13,482
                                    -----------    -----------     ------------    ------------

Total Other Income [Expense]            107,633         84,800          285,478       1,398,908
                                    -----------    -----------     ------------    ------------

Income Before Income Taxes              399,625        305,963        1,316,547       1,926,603

Federal and State Income Tax Expense    181,871        164,650          585,461         755,892
                                    -----------    -----------     ------------    ------------

Net Income                          $   217,754    $   141,313     $   731,086     $  1,170,711
                                    ===========    ===========     ===========     ============

Net Income Per Common Share:
Basic                               $       .03    $       .02     $        .11    $        .19
                                    ===========    ===========     ============    ============
Diluted                             $       .02    $       .02     $        .09    $        .17
                                    ===========    ===========     ============    ============

Average Common Shares Outstanding     7,543,034      6,228,720        6,660,429       6,228,720

Dilutive Potential Common Shares:
Options                               2,533,775      1,141,578        1,551,781         864,091
                                    -----------    -----------     ------------    ------------

Average Common Shares
Outstanding-assuming dilution        10,076,809      7,370,298        8,212,210       7,092,811
                                    ===========    ===========     ============    ============

</TABLE>

See accompanying notes to condensed consolidated financial statements.

                                       4


<PAGE>


INTEGRATED BIOPHARMA, INC.

CONSOLIDATED STATEMENT OF CASH FLOWS
[UNAUDITED]
--------------------------------------------------------------------------------

<TABLE>
<CAPTION>
                                                         Nine months ended
                                                              March 31,
                                                         -----------------

                                                         2003            2002
                                                         ----            ----
                                                       (Restated)
<S>                                                    <C>           <C>
Operating Activities:
  Net Income                                           $   731,086   $ 1,170,711
                                                       -----------   -----------
  Adjustments to Reconcile Net Income to Net Cash
    [Used for] Provided By Operating Activities:
    Depreciation and Amortization                          341,766       262,912
    Deferred Income Taxes                                   30,000       109,000
    Bad Debt Expense                                         5,024        89,391
    Gain on Sale of Fixed Assets                          (24,346)            --
  Changes in Assets and Liabilities
  (excludes impact of acquisitons)
    [Increase] Decrease in:
      Accounts Receivable                                  792,475       494,535
      Inventories                                      (1,573,555)       488,841
      Refundable Federal Income Taxes                     (81,231)       625,000
      Due From NuCycle Therapy, Inc. - Related Party        92,646      (53,051)
      Prepaid Expenses and Other Current Assets          (547,159)      (97,079)
      Security Deposits and Other Assets                     1,141      (18,592)
    [Decrease] Increase in:
      Accounts Payable                                     289,139     (626,457)
      Federal and State Income Taxes Payable                97,738       238,850
      Accrued Expenses and Other Liabilities              (79,486)     (487,859)
                                                       -----------   -----------

Total Adjustments                                        (655,848)     1,025,491
                                                       -----------   -----------

Net Cash - Operating Activities - Forward                   75,238     2,196,202
                                                       -----------   -----------

Investing Activities:
    Proceeds from Sale of Fixed Assets                      40,000
    Patents                                              (355,000)            --
    Loans to Stockholders                                  (9,505)      (68,746)
    Repayment of Note Receivable                                --       173,993
    Note Receivable             --                              --     (141,050)
    Purchase of Property and Equipment                   (325,060)     (259,067)
                                                       -----------   -----------

Net Cash - Investing Activities - Forward                (649,565)     (294,870)
                                                       -----------   -----------

Financing Activities:
  Exercise of Stock Options                                101,250            --
  Proceeds from Notes Payable                            2,255,954     2,507,245
  Repayment of Notes Payable                           (2,269,989)   (3,258,313)
                                                       -----------   -----------
Net Cash - Financing Activities - Forward                   87,215     (751,068)
                                                       -----------   -----------

</TABLE>

See accompanying notes to condensed consolidated financial statements.

                                       5


<PAGE>


INTEGRATED BIOPHARMA, INC.

CONSOLIDATED STATEMENT OF CASH FLOWS
[UNAUDITED]
--------------------------------------------------------------------------------

<TABLE>
<CAPTION>
                                                         Nine months ended
                                                              March 31,
                                                         -----------------

                                                         2003            2002
                                                         ----            ----
                                                       (Restated)

<S>                                                  <C>             <C>
Net Cash - Operating Activities - Forwarded               75,238       2,196,202

Net Cash - Investing Activities - Forwarded            (649,565)       (294,870)

Net Cash - Financing Activities - Forwarded               87,215       (751,068)
                                                     -----------     -----------

Net Increase/[Decrease] in Cash and Cash Equivalents   (487,112)       1,150,264

Cash and Cash Equivalents - Beginning of Periods       2,124,325         375,584
                                                     -----------     -----------

Cash and Cash Equivalents - End of Periods           $ 1,637,213     $ 1,525,848
                                                     ===========     ===========

Supplemental Disclosures of Cash Flow Information:
  Cash paid during the periods for:
    Interest                                         $     4,469     $    41,584
    Income Taxes                                     $   523,301     $   405,425

Supplemental Schedule of Investing and
Financial Activities:
Common Stock issued for acquisition
of NuCycle Therapy, Inc.                             $   175,196              --
Common Stock issued for acquisition
of Natex, LLC                                        $ 1,598,276              --

</TABLE>

See accompanying notes to condensed consolidated financial statements.

                                       6


<PAGE>


INTEGRATED BIOPHARMA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
[UNAUDITED]
--------------------------------------------------------------------------------

[1] Business

Effective April16, 2003, the Company amended its corporate charter and changed
its name to "Integrated  BioPharma,  Inc." (formerly Integrated Health
Technologies, Inc.) and began trading on the American Stock Exchange using the
symbol INB for its common stock.

Integrated BioPharma, Inc. [the "Company"] is engaged primarily in the
manufacturing,  marketing and sales of vitamins,  nutritional supplements  and
herbal  products.  Its  customers  are located  primarily  throughout  the
United  States.  The Company  considers all operations as one segment of
business.

[2] Summary of Significant Accounting Policies

Principles of Consolidation - The accompanying consolidated financial statements
include the accounts of the Company and its subsidiaries, all of which are
wholly owned. Inter-company transactions and balances have been eliminated in
consolidation.

Basis of Reporting - The accompanying unaudited interim financial statements
have been prepared in accordance with generally accepted accounting principles
for interim financial information and with the instructions to Form 10-QSB and
Item 310(b) of Regulation S-B. Accordingly, they do not include all of the
information and footnotes required by generally accepted accounting principles
for complete financial statements. In the opinion of management, such interim
statements include all adjustments, which are considered necessary in order to
make the interim financial statements not misleading. It is suggested that these
financial statements be read in conjunction with the financial statements and
notes thereto, together with management's discussion and analysis of financial
condition and results of operations, contained in the Company's annual report to
stockholders incorporated by reference in the Company's annual report on Form
10-KSB for the fiscal year ended June 30, 2002. The results of operations for
the nine months ended March 31, 2003 are not necessarily indicative of the
results for the entire fiscal year ending June 30, 2003.

Fair Value of Financial Instruments

Generally accepted accounting principles require disclosing the fair value of
financial instruments to the extent practicable for financial instruments which
are recognized or unrecognized in the balance sheet. The fair value of the
financial instruments disclosed herein is not necessarily representative of the
amount that could be realized or settled, nor does the fair value amount
consider the tax consequences of realization or settlement.

In assessing the fair value of financial instruments, the Company uses a variety
of methods and assumptions, which are based on estimates of market conditions
and risks existing at the time. For certain instruments, including cash and cash
equivalents, accounts receivable, accounts payable, and accrued expenses, it was
estimated that the carrying amount approximated fair value because of the short
maturities of these instruments. All debt is based on current rates at which the
Company could borrow funds with similar remaining maturities and approximates
fair value.

                                       7



<PAGE>


INTEGRATED BIOPHARMA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Sheet #2
[UNAUDITED]
--------------------------------------------------------------------------------

[2] Summary of Significant Accounting Policies (Continued)

Cash and Cash Equivalents - Cash equivalents are comprised of certain highly
liquid investments with a maturity of three months or less when purchased.

Inventories - Inventory is valued by the first-in, first-out method, at the
lower of cost or market.

Depreciation - The Company follows the general policy of depreciating the cost
of property and equipment over the following estimated useful lives:

Building                                                       15  Years
Leasehold Improvements                                         15  Years
Machinery and Equipment                                         7  Years
Machinery and Equipment Under Capital Leases                    7  Years
Transportation Equipment                                        5  Years

Machinery and equipment are depreciated using accelerated methods while
leasehold improvements are amortized on a straight-line basis. Depreciation
expense was $291,766 and $262,912 for the nine months ended March 31, 2003 and
2002, respectively. Amortization of equipment under capital leases is included
with the depreciation expense.

Estimates - The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts or revenues and expenses during the
reporting period. Actual results could differ from those estimates.

Revenue Recognition - The Company generally recognizes revenue upon shipment of
the product. All returns and allowances are estimated and recorded on a timely
basis.

Advertising - Costs incurred for producing and communicating advertising are
expensed when incurred. Advertising expense was $5,837 and $90,596 for the nine
months ended March 31, 2003 and 2002 respectively.

[3] Inventories

Inventories consist of the following at March 31, 2003:

Raw Materials                                                        $ 1,485,469
Work-in-Process                                                        1,000,781
Finished Goods                                                         1,792,966
                                                                     -----------

                                                                     $ 4,279,216
Total                                                                ===========

                                       8


<PAGE>


INTEGRATED BIOPHARMA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Sheet #3
[UNAUDITED]
--------------------------------------------------------------------------------

[4] Property and Equipment

Property and equipment comprise the following at March 31, 2003:

Land and Building                                                    $ 1,250,000
Leasehold Improvements                                                 1,163,360
Machinery and Equipment                                                2,866,307
Machinery and Equipment Under Capital Leases                             156,561
Transportation Equipment                                                  37,714
                                                                     -----------
Total                                                                  5,473,942
Less:  Accumulated Depreciation and Amortization                       3,148,775
                                                                     -----------

    Total                                                            $ 2,325,167
                                                                     ===========

[5] Notes Payable

On January 21, 2003 the Company terminated its existing credit line agreement
with Merchants Bank. At the termination date there were no balances due.

[6] Capital Lease

The Company acquired warehouse and office equipment under the provisions of two
long-term leases. The leases expire in July 2003, and February 2005,
respectively. The equipment under the capital leases as of March 31, 2003 has a
cost of $47,016 and accumulated depreciation of $21,971 with a net book value of
$25,045.

The future minimum lease payments under capital leases and the net present value
of the future minimum lease payments at March 31, 2003 are as follows:

Total Minimum Lease Payments                                            $ 47,016
Amount Representing Interest                                            (32,826)
                                                                        --------

Present Value of Net Minimum Lease Payment                                14,190
Current Portion                                                          (8,597)
                                                                        --------

  Long-Term Capital Lease Obligation                                    $  5,593
                                                                        ========

                                       9


<PAGE>


INTEGRATED BIOPHARMA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Sheet #4
[UNAUDITED]
--------------------------------------------------------------------------------

[6] Capital Lease (Continued)

The following are maturities of long-term capital lease obligations:

March 31,

2004                    $  8,597
2005                       5,593
2006                          --
2007                          --
                        --------
Total                   $ 14,190
                        ========

[7] Significant Risks and Uncertainties

[A] Concentrations of Credit Risk - Cash - The Company maintains balances at
several financial institutions. Accounts at each institution are insured by the
Federal Deposit Insurance Corporation up to $100,000. At March 31, 2003 the
Company's uninsured cash balances totaled approximately $1,850,000.

[B] Concentrations of Credit Risk - Receivables - The Company routinely assesses
the financial strength of its customers and, based upon factors surrounding the
credit risk of its customers, establishes an allowance for uncollectible
accounts and, as a consequence, believes that its accounts receivable credit
risk exposure beyond such allowances is limited. The Company does not require
collateral in relation to its trade accounts receivable credit risk. The amount
of the allowance for uncollectible accounts at March 31, 2003 is $29,460.

[8] Major Customer

For the nine months ended March 31, 2003 and 2002 approximately 68% and 56% of
revenues were derived from one customer. The loss of this customer would have an
adverse effect on the Company's operations. Two other customers accounted for
11% of consolidated sales for the nine months ended March 31, 2003 and 16% of
consolidated sales for the nine months ended March 31, 2002. Accounts receivable
from these customers comprised approximately 58% and 38% of total accounts
receivable at March 31, 2003 and 2002, respectively.

[9] Commitments and Contingencies

[A] Leases

Related Party Leases - Warehouse and office facilities are leased from Vitamin
Realty  Associates,  L.L.C.,  a limited  liability company,  which is 90% owned
by the Company's Chairman of the Board and principal  stockholder and certain
family members and 10% owned by the Company's  Chief  Financial Officer. The
lease was  effective on January 10, 1997 and provides for a minimum  annual
rental of $346,000 through January 10, 2002 plus increases in real estate taxes
and building operating  expenses.  At its option, the Company has the right to
renew the lease for an additional  five year period.  On April 28, 2000 the
lease was amended reducing the square footage and extending the lease to May 31,
2015. Rent expense for the nine months ended March 31, 2003 and 2002 on this
lease was approximately $350,000 and $340,000 respectively.

                                       10


<PAGE>


INTEGRATED BIOPHARMA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Sheet #5
[UNAUDITED]
--------------------------------------------------------------------------------

[9] Commitments and Contingencies (Continued)

Other Lease Commitments - The Company leases warehouse equipment for a five-year
period providing for an annual rental of $15,847 and office equipment for a five
year period providing for an annual rental of $8,365.

The Company leases automobiles under non-cancelable operating lease agreements,
which expire through 2006.

The minimum rental commitment for long-term non-cancelable leases is as follows:

                                   Related
                 Lease           Party Lease
March 31,      Commitment        Commitment          Total
---------      ----------        -----------         -----

2004           $  56,083        $   323,559       $   379,642
2005              34,465            323,559           358,024
2006              24,012            323,559           347,571
2007               7,697            323,559           331,256
2008                  --            323,559           323,559
Thereafter            --          2,283,687         2,283,687
               ---------        -----------       -----------
Total          $ 122,257        $ 3,901,482       $ 4,023,739
               =========        ===========       ===========

Total rent expense, including real estate taxes and maintenance charges, was
approximately $420,000 and $387,000 for the nine months ended March 31, 2003 and
2002, respectively. Rent expense is stated net of sublease income of
approximately $6,700 and $800 for the nine months ended March 31, 2003 and 2002,
respectively.

[B] Employment Agreement - Effective February 24, 2003, the Company entered into
an employment agreement with an executive, which expires on December 31, 2004
and provides for an aggregate annual salary of $100,000.

[C] Development and Supply Agreement - On April 9, 1998, the Company signed a
development and supply agreement with Herbalife International of America, Inc.
["Herbalife"] whereby the Company will develop, manufacture and supply certain
nutritional products to Herbalife through December 31, 2004. On December 31,
2002 the agreement was modified extending the term of the agreement to December
31, 2005 and providing that Herbalife is required to purchase a minimum quantity
of Supplied Products each year for the term of the agreement of $18,000,000. If
Herbalife purchases the minimum amount then Herbalife will be entitled to
certain rebates.

                                       11


<PAGE>


INTEGRATED BIOPHARMA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Sheet #6
[UNAUDITED]
--------------------------------------------------------------------------------

[10] Related Party Transactions

During the year ended June 30, 1997, the Company entered into a consulting
agreement with the brother of the Company's chairman of the board on a month to
month basis for $1,100 per month. The total consulting expense recorded per this
verbal agreement for the nine months ended March 31, 2003 and 2002, by the
Company was $9,900 and $9,900, respectively. See note 9(A) and notes 12(C) and
12(D).

[11] New Accounting Pronouncements

In July 2001, FAS No. 141, "Business Combinations" (FAS 141) and FAS No. 142
"Goodwill and Other Intangible Assets" (FAS 142) were issued. FAS 141 requires
that the purchase method of accounting be used for all business combinations
initiated after June 30, 2001. FAS 141 also specifies the criteria that
intangible assets acquired in a purchase method business combination must meet
to be recognized and reported apart from goodwill. FAS 142 requires that
goodwill and intangible assets with indefinite useful lives no longer be
amortized, but instead be tested for impairment, at least annually, in
accordance with the provisions of FAS 142. FAS 142 will also require that
intangible assets with definite useful lives be amortized over their respective
estimated useful lives to their estimated residual values, and be reviewed for
impairment in accordance with FAS No. 121, "Accounting for the Impairment of
Long-lived Assets and Long-lived Assets to be Disposed of". The provisions of
FAS 141 are effective immediately, except with regard to business combinations
prior to July 1, 2001. FAS 142 was effective as of July 1, 2002. Goodwill and
other intangible assets acquired in business combinations completed before July
1, 2001, will continue to be amortized prior to the adoption of FAS 142. The
adoption of FAS 142 did not have a material impact on the financial position and
results of operations.

In August 2001, the FASB issued SFAS No. 144, "Accounting for the Impairment of
Long-Lived Assets and for Long-Lived Assets to be disposed of." SFAS No. 144
establishes a single accounting model for long-lived assets to be disposed of by
sale and requires that those long-lived assets be measured at the lower of
carrying amount of fair value less cost to sell, whether reported in continuing
operations or in discontinued operations. SFAS No. 144 is effective for fiscal
years beginning after December 15, 2001. The adoption of this statement did not
have a material impact on its financial position and results of operations.

[12] Equity Transactions

[A] Incentive Stock Options-On February 4, 2003, the Company granted 117,647
incentive stock options for a term of ten years commencing on February 4, 2003
to an employee at the exercise price of $.85 (representing the market price) per
share and on February 24, 2003 the Company granted 57,142 incentive stock
options for a term of ten years commencing on February 24, 2003 to an employee
at the exercise price of $1.75 (representing the market price) per share.

[B] Non-Statutory Stock Options-On January 31, 2003 the Company granted 4,000
non-statutory stock options to members of its scientific advisory board at the
exercise price of $.75 (representing the market price) per share for a term of
ten years commencing on January 31, 2003. On February 4, 2003, the Company
granted 332,353 non-statutory stock options to an employee and a consultant at
the exercise price of $.85 (representing the market price) per share for a term
of ten years commencing on February 4, 2003 and on February 24, 2003

                                       12


<PAGE>


INTEGRATED BIOPHARMA, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Sheet #7
[UNAUDITED]
--------------------------------------------------------------------------------

[12] Equity Transactions [Continued]

the Company granted 92,858 non-statutory stock options for a term of ten years
commencing on February 4, 2003 to an employee at the exercise price of $1.75
(representing the market price) per share.

[C] Acquisitions-NuCycle Transaction

 On February 21, 2003, the Company completed a merger pursuant to an Agreement
and Plan of Merger dated as of February 21, 2003 between and among the Company,
NAC-NJ Acquisition Corp., a wholly-owned subsidiary of the Company (Acquisition
Sub") and NuCycle Acquisition Corp. ("NuCycle") pursuant to which the Company
acquired 100 percent of NuCycle Common Stock in exchange for the shareholders of
NuCycle receiving from the Company 368,833 shares of common stock at a market
value of $175,196 and a contingent consideration of twenty-five percent (25%) of
the after-tax profits of NuCycle until the shareholders of NuCycle have
received, in the aggregate, an additional $5,000,000 commencing with the first
fiscal quarter following the date of filing of the Certificate of Merger with
the New Jersey Department of Treasury. As of March 31, 2003 the likelihood of
such additional payments was not probable and in accordance with SFAS 141, no
such amount was recorded.

The NuCycle acquisition allows the Company to enter the field of genetically
engineered human therapeutics through NuCycle's expertise and its grant from the
National Cancer Institute.

The Company acquired assets of $153,709 and liabilities of $268,791 (at
carryover basis). Due to this related party transaction, the excess amount paid
over book value has reduced additional paid-in capital by $115,820. The
transactions of NuCycle for the month ended March 31, 2003 have been included in
the consolidated financial statements of the Company.

E.Gerald Kay, the Chairman of the Board of the Company, and a principal
stockholder of the Company, Seymour Flug, the President and Chief Executive
Officer of the Company, and Carl DeSantis, the father of Dean DeSantis who is a
director of the Company, collectively own approximately seventy-four percent
(74%) of NuCycle.

[D] Acquisitions-Natex LLC Acquisition

On February 24, 2003, the Company completed the acquisition of the membership
interests of Natex Georgia, LLC, a limited liability company formed under the
laws of the Republic of Georgia ("Natex") from Trade Investment Services, L.L.C.
("TIS") representing fifty percent (50)% of the membership interests of Natex.
Pursuant to the terms of a purchase agreement dated as of February 1, 2003 by
and between the Company and TIS, TIS received 2,458,886 shares of the Company's
common stock at a market value of $1,598,276 (based on the stock price 15 days
before and after such date. Such acquisition was attributable primarily to the
license agreement described below.

Since this is a common controlled related party transaction, the Company
recorded the investment using the carryover basis of zero. The common shares
issued in connection with this acquisition were recorded at fair market value.
Such amount then reduced paid in capital in accordance with accounting for
transactions with common control entities.

                                       13


<PAGE>


INTEGRATED BIOPHARMA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Sheet #8
[UNAUDITED]
--------------------------------------------------------------------------------

[12] Equity Transactions (Continued)

Natex is a recently formed company engaged in the business of harvesting and
collecting taxis bacatta botanical materials from government properties in the
Republic of Georgia, pursuant to a license from and supervision by the Georgian
government. Natex processes the materials to extract Paclitaxel and intends to
sell the extract to Paxis Pharmaceuticals Inc. ("Paxis") pursuant to an
exclusive supply contract with Paxis. Paxis is a Delaware company formed to
convert the extract to finished U.S.P. Paclitaxel in its Boulder, Colorado
facilities with the intention of selling that bulk Paclitaxel to other entities
which, in turn, convert it to dosage form or combine it with other substances,
in both cases for sale and distribution as a cancer therapy drug. Both Natex and
Paxis were formed last year. Neither company has any revenue to date.
Significant additional capital will be needed by both companies to begin selling
the bulk Paclitaxel. Both companies will be subject to various risks associated
with a new venture including, among others: operating in a foreign country which
may have political, economic, legal and regulatory environment which may differ
significantly from the U.S including the exporting of products, repatriation of
capital and exchange rate fluctuations; setting up manufacturing facilities;
complying with regulatory requirements for manufacturing pharmaceutical
products; marketing and selling the product; and operating profitably. There can
be no assurance that these companies can be operated profitably.

E. Gerald Kay, the Chairman of the Board of the Company and beneficial owner of
approximately fifty percent (50%) of the stock of the Company (or, approximately
sixty-two percent (62%) if family trusts of which he is a trustee are attributed
to him), is the owner of one-third (1/3) of the equity of TIS. Carl DeSantis,
the father of Dean DeSantis who is a director of the Company, is the owner of
one-third (1/3) of the equity of TIS.

[E] Acquisitions-Paxis Acquisition

The Company and Trade Investment Services, L.L.C. ("TIS") have entered into a
purchase agreement dated as of February 1, 2003 (the "Paxis Purchase Agreement")
pursuant to which the Company has agreed to purchase all of the interests of TIS
in TisorEx, Inc. (to be renamed Paxis Pharmaceuticals, Inc. or "Paxis") which
consists of fifty percent (50%) of the common stock of Paxis in exchange for
$500,000 payable at the closing and a contingent consideration of twenty-five
percent (25%) of the after-tax profits of Paxis commencing with the first
calendar quarter following the closing date until TIS has received an additional
$49,500,000 in the aggregate. The transaction closed July 22, 2003 and is more
fully described in the June 30, 2003 Form 10K.

                                       14


<PAGE>


Item 2.

INTEGRATED BIOPHARMA, INC.
MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
--------------------------------------------------------------------------------

The Company is restating its previously issued financial statements for the
quarter ended March 31, 2003 to correct an error in the accounting treatment
related to previously disclosed acquisition costs. The amount presented herein
reflect the restatement of these financial statements.

It was determined that the acquisition of 50% of Natex LLC, described in note
13D was with a controlled related party and that the investment should be
recorded at carryover basis (zero). The common shares issued (market value
$1,598,276) was recorded at market value. Such amount then reduced paid in
capital in accordance with accounting for transactions with common control
entities. There are no changes to the statement of operations.

The following discussion should be read in conjunction with the historical
information of the Company and notes thereto.

Nine months ended March 31, 2003 Compared to nine months ended March 31, 2002

Results of Operations

The Company's net income for the nine months ended March 31, 2003 was $731,086
as compared to net income of $1,170,711 for the nine months ended March 31,
2002. This decrease in net income of approximately $440,000 is primarily the
result of a $505,000 increase in operating income resulting from a corresponding
increase in gross profit of approximately $405,000, a decrease in other income
of approximately $1,100,000 due to the settlement of a Class Action Lawsuit and
a decrease in Federal and state income taxes of approximately $170,000.

Sales for the nine months ended March 31, 2003 and 2002 were $17,464,163 and
$16,739,241 respectively, an increase of approximately $725,000 or 4%. For the
nine months ended March 31, 2003 the Company had sales to one customer, who
accounted for 68% of net sales in 2003 and 56% in 2002. The loss of this
customer would have an adverse affect on the Company's operations.

Retail and mail order sales for the nine months ended March 31, 2003 totaled
$80,290 as compared to $145,316 for the nine months ended March 31, 2002, a
decrease of 45%. The Company has been experiencing a decline in mail order sales
due to increased competition. The Company closed its retail store on March 2,
2001.

Sales under the Roche Vitamins, Inc. distribution agreement were $1,687,244 for
the nine months ended March 31, 2003 as compared to $1,834,634 for the nine
months ended March 31, 2002, a decrease of $147,390 or 8%.

On August 31, 2000, the Company began the distribution and sale of fine
chemicals through a new subsidiary, IHT Health Products, Inc. Sales for the nine
months ended March 31, 2003 totaled $1,537,835 as compared to $2,520,932 for the
nine months ended March 31, 2002, a decrease of $983,097 or 39%. The decrease in
sales is due to Company's desire to pursue greater gross profit at the risk of
lower sales.

                                       15

<PAGE>


INTEGRATED BIOPHARMA, INC.
MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
--------------------------------------------------------------------------------

Results of Operations (Continued)

On February 21, 2003 the Company merged with NuCycle Acquisition Corp.
("NuCycle"). NuCycle through its wholly-owned subsidiary, NuCycle Therapy, Inc.
is engaged in the development and sale of nutritional formulations based on
plant-derived minerals through patented hyperaccumulation technology. Sales for
the month ended March 31, 2003 totaled $ 9,120.

Cost of sales increased to $13,564,430 for the nine months ended March 31, 2003
as compared to $13,245,102 for the nine months ended March 31, 2002. Cost of
sales decreased as a percentage of sales to 78% for the nine months ended March
31, 2003 from 79% for the nine months ended March 31, 2002. The decrease in cost
of sales is due to greater manufacturing efficiencies.

A tabular presentation of the changes in selling and administrative expenses is
as follows:

                                         Nine Months Ended
                                             March 31,
                                         -----------------

                                      2003            2002              Change
                                      ----            ----              ------

Advertising                        $     5,837     $    90,596        $ (84,759)
Bad Debt Expense                         5,024          89,391          (84,367)
Royalty and Commission Expense          48,613          75,251          (26,638)
Officers Salaries                      361,531         242,910           118,621
Auto, Travel & Entertainment           394,762         321,427            73,335
Office Salaries                        584,853         799,444         (214,591)
Office Expenses                         91,898         138,815          (46,917)
Public Relations Fees                       --          23,457          (23,457)
Consulting Fees                        323,056         177,133           145,923
Depreciation & Amortization            179,432         129,268            50,164
Freight Out                             77,663         166,485          (88,822)
Other                                  795,995         722,267            83,728
                                   -----------     -----------        ----------
Total                              $ 2,868,664     $ 2,966,444        $ (97,780)
                                   ===========     ===========        ==========

Advertising expenses decreased because the Company has decided to spend less on
advertising and place a greater emphasis on its contract manufacturing business.
The decrease in bad debt expense is due to greater emphasis on the Company's
credit policies. Royalty and commission expense has decreased because the sales
of raw materials that incur royalty and commission expense had decreased by
$983,097. Officers' salaries have increased because of the addition of a new
corporate Vice President. Auto, travel and entertainment expenses have increased
because of increased travel. Office salaries have decreased because of the
elimination of four positions, two in the IHT Ideas, Inc. subsidiary and two in
the IHT Health Products, Inc. subsidiary. Office expenses have decreased due to
lower costs for computer consultants. Public relation fees have decreased due to
the termination of the Company's public relations firm. The increase in
consulting fees is due to the hiring of a consulting firm for a new water
monitoring system. Depreciation and amortization have increased due to the
purchase of additional property and equipment. Freight out has decreased due to
the reduction of sales in the Company's IHT Health Products, Inc. subsidiary by
$983,097.

                                       16

<PAGE>


INTEGRATED BIOPHARMA, INC.
MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
--------------------------------------------------------------------------------

Results of Operations (Continued)

Other income [expense] was $285,478 for the nine months ended March 31, 2003 as
compared to $1,398,908 for the nine months ended March 31, 2002. The decrease of
$1,113,430 is primarily the result of the proceeds received of $1,157,960 from
the settlement of a Class Action Lawsuit in 2001.

Inventories

The inventory at March 31, 2003 increased by $1,573,555 from fiscal 2002. The
Company produces products on a purchase order basis. The increase in inventory
is attributable to an increase in work in process and finished goods inventory
of approximately $1,163,000 and an increase in raw material inventory of
approximately $410,000. The increase in finished goods is because the Company's
main customer is utilizing a just in time inventory system and has requested
that the Company maintain the finished goods inventory in our warehouse.

Prepaid Expenses

Prepaid Expenses and other current assets increased by $547,159 from June 30,
2002. The increase is attributable to an increase in prepaid insurance of
$434,936 because the Company acquired a five-year products liability policy for
a certain product and was required to pay the entire five year premium in
advance. Also, prepaid travel expenses increased by $44,580 due to an advance
for airline travel and prepaid research expenses increased by $75,000 due to the
acquisition of NuCycle Therapy, Inc.

Three months ended March 31, 2003 Compared to three months ended March 31, 2002

The Company's net income for the three months ended March 31, 2003 was $217,754
as compared to net income of $141,313 for the three months ended March 31, 2002.
This increase in net income of approximately $76,000 is primarily the result of
a $70,000 increase in operating income resulting from a corresponding increase
in gross profit of approximately $200,000, an increase in selling and
administrative expenses of approximately $125,000 and an increase in Federal and
state income taxes of approximately $17,000.

Sales for the three months ended March 31, 2003 and 2002 were $6,670,254 and
$5,278,366 respectively, an increase of approximately $1,390,000 or 26%. For the
three months ended March 31, 2003 the Company had sales to one customer, who
accounted for 72% of net sales in 2003 and 62% in 2002. The loss of this
customer would have an adverse affect on the Company's operations.

Retail and mail order sales for the three months ended March 31, 2003 totaled
$26,465 as compared to $45,504 for the three months ended March 31, 2002, a
decrease of 42%. The Company has been experiencing a decline in mail order sales
due to increased competition. The Company closed its retail store on March 2,
2001.

Sales under the Roche Vitamins, Inc. distribution agreement were $679,096 for
the three months ended March 31, 2003 as compared to $599,256 for the three
months ended March 31, 2002, an increase of $79,840 or 13%.

                                       17


<PAGE>


INTEGRATED BIOPHARMA, INC.
MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
--------------------------------------------------------------------------------

Results of Operations (Continued)

IHT Health Products, Inc. sales for the three months ended March 31, 2003
totaled $570,567 as compared to $825,484 for the three months ended March 31,
2002, a decrease of $254,917 or 31%. The decrease in sales is due to the
Company's desire to pursue greater gross profit at the risk of lower sales.

Cost of sales increased to $5,266,734 for the three months ended March 31, 2003
as compared to $4,072,267 or the three months ended March 31, 2002. Cost of
sales increased as a percentage of sales to 79% for the three months ended March
31, 2003 from 77% for the three months ended March 31, 2002. The increase in
cost of sales is due to differences in the product mix.

A tabular presentation of the changes in selling and administrative expenses is
as follows:

                                         Three Months Ended
                                              March 31,
                                         ------------------

                                        2003            2002            Change
                                        ----            ----            ------

Advertising                            $ 1,200        $ 74,263        $ (73,063)
Bad Debt Expense                       (1,869)          32,609          (34,478)
Officers Salaries                      117,077          79,724            37,353
Auto, Travel & Entertainment           123,301         100,029            23,272
Office Salaries                        188,319         244,622          (56,303)
Professional Fees                       87,029          27,183            59,846
Consulting Fees                        197,928          46,916           150,212
Freight Out                             23,499          68,169          (44,670)
Other                                  375,844         311,421            64,423
                                   -----------     -----------      ------------
Total                              $ 1,111,528     $ 2,966,444      $  (126,592)
                                   ===========     ===========      ============

Advertising expenses decreased because the Company has decided to spend less on
advertising and place a greater emphasis on its contract manufacturing business.
The decrease in bad debt expense is due to greater emphasis on the Company's
credit policies. Officers' salaries have increased because of the addition of a
new corporate Vice President. Auto, travel and entertainment expenses have
increased because of increased travel. Office salaries have decreased because of
the elimination of four positions, two in the IHT Ideas, Inc. subsidiary and two
in the IHT Health Products, Inc. subsidiary. Professional fees increased due to
the acquisitions the Company made in the current quarter. The increase in
consulting fess is due to the hiring of a consulting firm for a new water
monitoring system and the hiring of a new sales representative. Freight out has
decreased due to a reduction of sales in the Company's IHT Health Products, Inc.
subsidiary by $254,917.

Other income [expense] was $107,633 for the three months ended March 31, 2003 as
compared to $84,800 for the three months ended March 31, 2002. The increase of
$22,833 is primarily the result of the gain on the sale of fixed assets of
$24,346.

                                       18


<PAGE>


INTEGRATED BIOPHARMA, INC.
MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OPERATIONS
--------------------------------------------------------------------------------

Results of Operations (Continued)

Liquidity and Capital Resources

At March 31, 2003 the Company's working capital was $5,515,306 an increase of
$615,742 over working capital at June 30, 2002. Cash and cash equivalents were
$1,637,213 at March 31, 2003, a decrease of $487,112 from June 30, 2002. The
Company generated $75,238 and $2,196,202 from operations for the nine months
ended March 31, 2003 and 2002, respectively.

The primary reasons for the decrease in cash provided for operations for the
nine months ended March 31, 2003 are net income of approximately $730,000, a
decrease in accounts receivable of approximately $800,000, an increase in
inventories of approximately $1,600,000, an increase in prepaid expenses of
approximately $550,000, an increase in accounts payable of approximately
$300,000 and a decrease in Federal and State Income Taxes Payable of
approximately $140,000.

The Company utilized $694,565 and $294,870 in investing activities for the nine
months ended March 31, 2003 and 2002, respectively. The Company generated
$87,215 and utilized net cash of $751,068 from debt financing activities for the
nine months ended March 31, 2003 and 2002, respectively.

The Company had a $1,000,000 revolving line of credit agreement, which bore
interest at 4% above the prime interest rate and expires on December 21, 2003.
On January 21, 2003 the Company terminated its credit line agreement.

The Company's total annual commitment at March 31, 2003 for the next five years
of $1,740,052 consists of obligations under operating leases for facilities and
lease agreements for the rental of warehouse equipment and automobiles.

The Company does not anticipate having to provide additional working capital for
the NuCycle Therapy acquisition and the Natex LLC acquisition. (See notes 12(C)
and 12(D)).

                                       19


<PAGE>


Item 3.

INTEGRATED BIOPHARMA, INC.
CONTROLS AND PROCEDURES

(a) Evaluation  of  disclosure  controls  and  procedures.  An  evaluation  was
    performed  under  the  supervision  and  with the participation of the
    Company's management,  including the Chief Executive Officer (CEO) and Chief
    Financial Officer (CFO), of the effectiveness of the design and operation of
    the Company's  disclosure  controls and procedures within 90 days before the
    filing date of this Form  10-QSB.  Based on their evaluation,  the Company's
    principal executive officer and  principal financial officer have concluded
    that the Company's  disclosure  controls and procedures (as defined in Rules
    13a-14(c) and 15d-14(c) under the Securities Exchange Act of 1934 (the
    "Exchange Act") are effective to ensure that  information  required to be
    disclosed by the Company in reports that it files or submits under the
    Exchange Act is recorded, processed, summarized and reported within the time
    periods specified in Securities and Exchange Commission rules and forms.

(b) Changes in internal controls. There have been no significant changes in the
    Company's internal controls or in other factors that could significantly
    affect internal controls subsequent to their evaluation. There were no
    significant deficiencies or material weaknesses, and therefore there were no
    corrective actions taken.

                                       20


<PAGE>


Part II:  Other Information

INTEGRATED BIOPHARMA, INC.

Item 1:         Legal Proceeding

                None

Item 2:         Changes in Securities

                None

Item 3:         Defaults Upon Senior Securities

                None

Item 4:         Submission of Matters to a Vote of Security Holders

                None

Item 5:         Other Information

                None

Item 6:         Exhibits and Reports on Form 8-K

                Current Report on Form 8-K filed January 2, 2003 pursuant to
                Item 5 (Other Events).

                Current Report on Form 8-K filed January 14, 2003 pursuant to
                Item 5 (Other Events).

                Current Report on Form 8-K filed February 21, 2003 pursuant to
                Item 5 (Other Events).

                Current Report on Form 8-K filed February 24, 2003 pursuant to
                Item 2 (Acquisition of Assets).

                Current Report on Form 8-K/A filed April 24, 2003 pursuant to
                Item 7 (Financial Statements, Pro Forma Financial Statements and
                Exhibits).

                                       21


<PAGE>


SIGNATURES
--------------------------------------------------------------------------------


Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.


                                           INTEGRATED BIOPHARMA, INC.

Date:   April 30, 2003                     By:/s/ Seymour Flug
                                           -------------------
                                           Seymour Flug,
                                           President and Chief Executive Officer


Date:   April 30, 2003                     By:/s/ Eric Friedman
                                           --------------------
                                           Eric Friedman,
                                           Chief Financial Officer

                                       22


<PAGE>


                              Certification of CFO

I, Eric Friedman, certify that:

1.   I have reviewed this quarterly report on Form 10-QSB of Integrated
     BioPharma Inc. (f/k/a Integrated Health Technologies, Inc.);

2.   Based on my knowledge, this quarterly report does not contain any untrue
     statement of a material fact or omit to state a material fact necessary to
     make the statements made, in light of the circumstances under which such
     statements were made, not misleading with respect to the period covered by
     this quarterly report;

3.   Based on my knowledge, the financial statements, and other financial
     information included in this quarterly report, fairly present in all
     material respects the financial condition, results of operations and cash
     flows of the registrant as of, and for, the periods presented in this
     quarterly report;

4.   The registrant's other certifying officers and I are responsible for
     establishing and maintaining disclosure controls and procedures (as defined
     in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

     a)   designed such disclosure controls and procedures to ensure that
          material information relating to the registrant, including its
          consolidated subsidiaries, is made known to us by others within those
          entities, particularly during the period in which this quarterly
          report is being prepared;

     b)   evaluated the effectiveness of the registrant's  disclosure  controls
          and procedures as of a date within 45 days prior to the filing date of
          this quarterly report (the "Evaluation Date"); and

     c)   presented in this quarterly report our conclusions about the
          effectiveness of the disclosure controls and procedures based on our
          evaluation as of the Evaluation Date.

5.   The registrant's other certifying officers and I have disclosed, based on
     our most recent evaluation, to the registrant's auditors and the audit
     committee of registrant's board of directors (or persons performing the
     equivalent function):

     a)   all significant deficiencies in the design or operation of internal
          controls which could adversely affect the registrant's ability to
          record, process, summarize and report financial data and have
          identified for the registrant's auditors any material weaknesses in
          internal controls; and

     b)   any fraud, whether or not material, that involves management or other
          employees who have a significant role in the registrant's internal
          controls; and

6.   The registrant's other certifying officers and I have indicated in this
     quarterly report whether or not there were significant changes in internal
     controls or in other factors that could significantly affect internal
     controls subsequent to the date of our most recent evaluation, including
     any corrective actions with regard to significant deficiencies and material
     weaknesses.

Date: April 30, 2003             By:/s/ Eric Friedman
                                 --------------------
                                 Name: Eric Friedman
                                 Title: Vice President & Chief Financial Officer


<PAGE>


                              Certification of CEO

I, Seymour Flug, certify that:

1.   I have reviewed this quarterly report on Form 10-QSB of Integrated
     BioPharma, Inc. (f/k/a Integrated Health Technologies, Inc.);

2.   Based on my knowledge, this quarterly report does not contain any untrue
     statement of a material fact or omit to state a material fact necessary to
     make the statements made, in light of the circumstances under which such
     statements were made, not misleading with respect to the period covered by
     this quarterly report;

3.   Based on my knowledge, the financial statements, and other financial
     information included in this quarterly report, fairly present in all
     material respects the financial condition, results of operations and cash
     flows of the registrant as of, and for, the periods presented in this
     quarterly report;

4.   The registrant's other certifying officers and I are responsible for
     establishing and maintaining disclosure controls and procedures (as defined
     in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

     a)   designed such disclosure controls and procedures to ensure that
          material information relating to the registrant, including its
          consolidated subsidiaries, is made known to us by others within those
          entities, particularly during the period in which this quarterly
          report is being prepared;

     b)   evaluated the  effectiveness of the registrant's  disclosure controls
          and procedures as of a date within 45 days prior to the filing date of
          this quarterly report (the "Evaluation Date"); and

     c)   presented in this quarterly report our conclusions about the
          effectiveness of the disclosure controls and procedures based on our
          evaluation as of the Evaluation Date.

5.   The registrant's other certifying officers and I have disclosed, based on
     our most recent evaluation, to the registrant's auditors and the audit
     committee of registrant's board of directors (or persons performing the
     equivalent function):

     a)   all significant deficiencies in the design or operation of internal
          controls which could adversely affect the registrant's ability to
          record, process, summarize and report financial data and have
          identified for the registrant's auditors any material weaknesses in
          internal controls; and

     b)   any fraud, whether or not material, that involves management or other
          employees who have a significant role in the registrant's internal
          controls; and

6.   The registrant's other certifying officers and I have indicated in this
     quarterly report whether or not there were significant changes in internal
     controls or in other factors that could significantly affect internal
     controls subsequent to the date of our most recent evaluation, including
     any corrective actions with regard to significant deficiencies and material
     weaknesses.


Date: April 30, 2003                  By:/s/ Seymour Flug
                                      -------------------
                                      Name: Seymour Flug
                                      Title: President & Chief Executive Officer


<PAGE>


                        CERTIFICATION OF PERIODIC REPORT

I, Seymour Flug, the President & Chief Executive Officer of Integrated
BioPharma,  Inc. (f/k/a Integrated Health  Technologies,  Inc.) (the "Company"),
certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C.
Section 1350, that:

(1)      the Quarterly Report on Form 10-QSB of the Company for the quarterly
         period ended March 31, 2003 (the "Report") fully complies with the
         requirements of Section 13(a) or 15(d) of the Securities Exchange Act
         of 1934 (15 U.S.C. 78m or 78o(d)); and

(2)      the information  contained in the Report fairly presents,  in all
         material  respects,  the financial  condition and results of operations
         of the Company.

Dated:   April 30, 2003


                                   By:/s/ Seymour Flug
                                   -------------------
                                   Seymour E. Flug
                                   President & Chief Executive Officer


                        CERTIFICATION OF PERIODIC REPORT

I,  Eric  Friedman, the Vice President and Chief Financial Officer of Integrated
BioPharma,  Inc. (f/k/a  Integrated  Health Technologies, Inc.) (the "Company"),
certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C.
Section 1350, that:

(1)      the Quarterly Report on Form 10-QSB of the Company for the quarterly
         period ended March 31, 2003 (the "Report") fully complies with the
         requirements of Section 13(a) or 15(d) of the Securities Exchange Act
         of 1934 (15 U.S.C. 78m or 78o(d)); and

(2)      the information  contained in the Report fairly presents, in all
         material  respects,  the financial condition and results of  operations
         of the Company.

Dated:   April 30, 2003


                                   By:/s/ Eric Friedman
                                   --------------------
                                   Eric Friedman
                                   Vice President and Chief Financial Officer